AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05284136 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral prednisolone
Description: oral prednisolone at an initial dose of 40 to 60 mg/day (or 1 mg/kg for those patients who weigh less than 40 kg), with a fixed, tapering regimen such that patients should be off steroids by the last day of week 12. Increases in steroid dose during tapering of corticosteroids is allowed but if the patient receives steroids (other than hydrocortisone for adrenal insufficiency) after week 12, he/she is in failure.
Study NCT05136846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT05136846 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV
Study NCT05136846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT05136846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Papaverine
Description: Given IV or SC
Study NCT05136846 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo RT
Study NCT05136846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Given IV
Study NCT06419517 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMG-triggered ES
Description: The ES treatment protocol consisted of daily endovaginal electrostimulation sessions for four weeks. We used a portable unit EVOSTIM ®, which allowed us to use different frequencies and length of impulse and a probe Perisphera ® The average current intensity was adjusted according to the sensation of discomfort in each patient.
Study NCT06419517 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic Floor Muscle Training
Description: Standardization of the supervised PFMT To achieve standardization of supervised PFMT treatments, a written protocol for the physiotherapeutic examinations and PFMT program will be provided to the physiotherapists (or nurse or midwife) delivering the treatments (See Additional file).
Study NCT06419517 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic Floor Muscle Training
Description: Standardization of the supervised PFMT To achieve standardization of supervised PFMT treatments, a written protocol for the physiotherapeutic examinations and PFMT program will be provided to the physiotherapists (or nurse or midwife) delivering the treatments (See Additional file).
Study NCT05580380 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Limited Relationship
Description: In this group, participants will share information regarding their low back pain history to a clinician who is not providing eye-contact, has farther physical distance, and is not directly facing the participant. The clinician will not provide verbal affirmations or ask clarifying questions about the patient's low back pain history. Instead, more time will be spent on completion of documentation.
Study NCT05580380 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Relationship
Description: A condition in which the clinician is providing enhanced relatedness with consistent eye contact, closer physical distance, facing the patient, and providing non-verbal affirmations (i.e. nodding, smiling), as the participant shares their low back pain history. The clinician will provide empathic verbal affirmations and will ask clarifying questions about the patient's low back pain history.
Study NCT04716153 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multifactorial sensory rehabilitation workshops
Description: A multifactorial sensory rehabilitation Workshops : a multifactorial program in order to optimize the recovery of flavors, focused on smell and taste which integrates several non-drug interventions, which are part of the current recommendations: hydration of the mucous membranes with daily (3 times a day) liposomal sprays (nose and mouth), presentation of visual dishes.
Study NCT04716153 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: The control group only receives the usual care provided for as part of routine care. It consists of a nutritional assessment at home by a dietician, with monitoring of intake and weight, in order to readjust nutritional support. A systematic search for oral mycosis is carried out in order to treat.~The foods that the patient prefers, identified from a list of authorized foods, are preferred or even fortified.
Study NCT04716153 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Tests and Questionnaire
Description: fulfillment of Taste Strips Test, Sniffin'sticks test and QGO, FACT-G, HADS, l'EVA des ingesta and GPAQ questionnaires to assess the quality of life of patients
Study NCT04716153 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tests and Questionnaire
Description: fulfillment of Taste Strips Test, Sniffin'sticks test and QGO, FACT-G, HADS, l'EVA des ingesta and GPAQ questionnaires to assess the quality of life of patients
Study NCT05130138 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmaceutical intervention
Description: Patients with pharmacokinetic and/or pharmacodynamics interactions will be proposed to participate to educational sessions to discuss about treatments taken and modifications possibilities.
Study NCT06082674 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vayu bCPAP
Description: The Vayu bCPAP uses a constant flow of dry oxygen from the source with an adjustable flow meter. Oxygen is blended by Venturi blender with ambient air to create a source of oxygen-enriched air of adjustable concentration.
Study NCT06082674 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Ventilator Driven CPAP
Description: Mechanical Ventilator Driven CPAP
Study NCT04750135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin 500 mg TID Oral Tablet
Description: biguanides derivatives
Study NCT04750135 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05174585 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JAB-BX102 (anti-CD73 monoclonal antibody)
Description: Administered by intravenous infusion (IV)
Study NCT05174585 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab (anti-PD-1 monoclonal antibody)
Description: Administered by intravenous infusion (IV)
Study NCT05924139 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid
Description: 6 capsules per day of 3840 mg that included 1950 mg EPA and 1350 mg DHA
Study NCT05924139 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 capsules per day of coconut oil
Study NCT06093464 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Natural Compound A (Hinoki essential oil)
Description: Participants will use Natural Compound A in a diffuser every night for 4 weeks. Diffuser will be placed near participant's bed and will be used during the entire time they are asleep (about 8 hours, every night).
Study NCT06093464 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Natural Compound B (Lemon essential oil)
Description: Participants will use Natural Compound B in a diffuser every night for 4 weeks. Diffuser will be placed near participant's bed and will be used during the entire time they are asleep (about 8 hours, every night).
Study NCT06093464 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Natural Compound C (Control/Water)
Description: Participants will use Natural Compound C in a diffuser every night for 4 weeks. Diffuser will be placed near participant's bed and will be used during the entire time they are asleep (about 8 hours, every night).
Study NCT06374966 — intervention group
Intervention type: DRUG
Intervention: Zonisamide
Description: This is a real-world study，so we prospectively enrolled patients with focal epilepsy suitable for taking zonisamide as an add-on medication
Study NCT04697862 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normobaric hypoxia (FiO2 15%) under Sildenafil
Description: Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour. given by a facemask, first at rest and then during exercise under Sildenafil.
Study NCT04697862 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normobaric hypoxia (FiO2 15%)
Description: Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise.
Study NCT05495581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pudexacianinium chloride
Description: Intravenous
Study NCT04596644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Investigates two strengths of cannabis.
Study NCT05293340 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Avocado Vouchers
Description: Food as Medicine to demonstrate clinically meaningful benefits for underserved communities. Avocados are fruits with fats, fiber, micronutrients, and bioactive phytochemicals.
Study NCT05035238 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Triple dose vaccination by inactivated Covid19 vaccine
Description: triple dose intramuscular vaccine on Day 0, Day 28, and Day 120.
Study NCT04481672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: Intravenous infusion of magnesium sulfate prior to intraoperative chemotherapy with cisplatin.
Study NCT05517564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-60106
Description: The participants will receive a single oral dose between 2.5 to 100 mg for Part A (SAD), Part B (MAD) once daily for 14 days, and for Part C (MAD) once daily for 28 days.
Study NCT05517564 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-to-match GM-60106 capsules
Study NCT06214533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5%
Description: Prior to the end of the laparoscopic surgery and any additional procedures, the bilateral celiac plexus block will be performed by the surgeon after identification of the aorta at the superior border of body of pancreas. A 22-gauge spinal needle will be inserted into the retroperitoneal fat on either side of the aorta under direct vision. Needle aspiration will be performed to exclude entry into vessels before administration of the interventional drug. The block will contain 20 mL of 0.5% ropivacaine hydrochloride + 1:400000 adrenaline.
Study NCT06214533 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Prior to the end of the laparoscopic surgery and any additional procedures, the bilateral celiac plexus block will be performed by the surgeon after identification of the aorta at the superior border of body of pancreas. A 22-gauge spinal needle will be inserted into the retroperitoneal fat on either side of the aorta under direct vision. Needle aspiration will be performed to exclude entry into vessels before administration of the interventional drug. The block will contain 20 ml of 0.9% normal saline + 1:400000 adrenaline.
Study NCT05709483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Platelet assays including VerifyNow Aspirin assay, VerifyNow Base assay, platelet aggregometry, Thromboxana A2 levels- will be measured at baseline and 1 hour after administration of single-dose enteric-coated 81 mg aspirin
Study NCT05947838 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Circulating tumoral DNA directed neoadjuvant therapy arm
Description: Given by IV (vein)
Study NCT04940728 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Creative thinking techniques intervention program
Description: The intervention program based on creative thinking techniques was designed to consist of four stages: preparation, theoretical briefing, skill development and evaluation. In the first stage of the program, acquaintance and information meeting, in the second stage, the theoretical part lasts for two weeks, in the third stage, various creative thinking techniques are applied for four weeks to gain creative thinking skills.
Study NCT04141319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: 30ml of local infiltration solution containing 60mg ropivacaine
Study NCT04141319 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: 30ml of local infiltration solution containing 6mg ketorolac
Study NCT04141319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 30ml of local infiltration solution containing 6mg ketorolac
Study NCT04141319 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: 30ml of local infiltration solution containing 0.1mg epinephrine
Study NCT04141319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: 30ml of local infiltration solution containing 0.1mg epinephrine
Study NCT05958589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caudal block with levobupivacaine
Description: After the introduction of general anesthesia, a single shot caudal block will be performed with levobupivacaine 0.25% (2.5 mg/kg; maximal dose 75 mg).
Study NCT05958589 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: On the day of operation all patients will recieve midazolam 0.5 mg/kg (maximum dose 15 mg) orally. Induction of anesthesia will be the same for all patients and consist of intravenous anesthetic propofol (2-3 mg/kg), opioid analgesic fentanyl (1-1.5 mcg/kg), and muscle relaxant rocuronium - bromide (0.6-1 mg/kg). The airway will be obtained by placing a laryngeal mask (I-gel®).
Study NCT05958589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: General anesthesia
Description: On the day of operation all patients will recieve midazolam 0.5 mg/kg (maximum dose 15 mg) orally. Induction of anesthesia will be the same for all patients and consist of intravenous anesthetic propofol (2-3 mg/kg), opioid analgesic fentanyl (1-1.5 mcg/kg), and muscle relaxant rocuronium - bromide (0.6-1 mg/kg). The airway will be obtained by placing a laryngeal mask (I-gel®).
Study NCT05958589 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inguinal hernioplasty
Description: Elective inguinal hernioplasty
Study NCT05958589 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inguinal hernioplasty
Description: Elective inguinal hernioplasty
Study NCT04752722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EG-70 (phase 1)
Description: Patients will receive up to four cycles of EG-70 administered as a bladder instillation of a 50 mL volume of study drug via catheter with a targeted retention time of 60 minutes.One cycle lasts approximately 12 weeks and consists of either a 2-dose (Day 1 and Day 8) or 4-dose (Day 1, Day 8, Day 29 and Day 36) regimen.
Study NCT04752722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EG-70 (phase 2)
Description: Cohort 1 and Cohort 2: Patients will receive up to 4 cycles of EG-70 at the RP2D defined in Phase 1 administered as a bladder instillation of a 50 mL volume of study drug via catheter with a targeted retention time of 60 minutes. One cycle lasts approximately 12 weeks.
Study NCT06493734 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy
Description: SBRT will be delivered in 15 fractions of 4 to 4.5Gy (risk-adapted), one fraction each weekday for 3 weeks.
Study NCT06341400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DisitamabVedotinForIicction Toripalimab
Description: Each subject will receive RC48-ADC 2.0mg/kg and toripalimab 3.0mg/kg intravenously every 2 weeks for a total of 4 cycles. RC48-ADC 2.0mg/kg and toripalimab 3.0mg/kg were intravenously infused every 2 weeks for 8 cycles.
Study NCT05670912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Wei Li Bai capsules
Description: The distribution ratio between the groups was 1:1, and the stratification factor was the degree of illness CDR score. In the study, the entry of each subject into the active group or placebo group will be determined by the randomized system.
Study NCT05670912 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator of Wei Li Bai capsules
Description: The distribution ratio between the groups was 1:1, and the stratification factor was the degree of illness CDR score. In the study, the entry of each subject into the active group or placebo group will be determined by the randomized system.
Study NCT05430711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinoprostone
Description: After randomization, participants will receive dinoprostone 10 mg vaginal delivery system which will remain in place up to 24 hours or until the labour begins. At the onset of labor or after 24h it will be removed and participant transferred to labour room for further standard procedures.
Study NCT04875403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle trainning
Description: linear load device, associated with the resisted training. The initial training load for each participant will be adjusted to 25% of MIP. Each week, the researcher determines the new values for load (1 to week 25%, 2 to week 35%;. 3 to week 40%;. 4 to week 45%;. 5 to week 50%.).
Study NCT04875403 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: exercise bike for 30 minutes, which will be divided into 10 minutes for the foot heating and 20 minutes for the workout aerobic exercise that will have to maintain a target training heart rate
Study NCT05521100 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vascular closure device
Description: Suture of lower extremity veins using the Proglide Vascular Closure Device
Study NCT05521100 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: figure eight stitch
Description: Vascular Sutures for Transvenous Cardiac Intervention Using Conventional Figure-8 Sutures
Study NCT04511442 — intervention group
Intervention type: OTHER
Intervention: Evaluation of food preferences during a standardized and validated buffet.
Description: The dietary preferences of people will be collected by a direct measurement of eating behavior in front of a dedicated and standardized ad-libitum buffet.~As part of this buffet, 3 dichotomous categories of food will be studied:~* high / low in fat (HF / LF)~* high / low in carbohydrates (HC / LC)~* high / low in protein (HP / LP). During the buffet, participants will be filmed to study their food choices and the microstructure of their meal. We will define food preferences as the relative consumption choices of the food categories studied. We will also collect the time spent at the buffet, the duration of ingestion, the total duration of the meal, the number of bites per minute, the total number of bites and the number of bites by type of food.~Weighing's will be carried out before and after consumption in order to determine the total energy intake and the macronutrient intake (proteins, lipids, carbohydrates) of the participants.
Study NCT05946759 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Histolog Scanner
Description: The PMPF study is collecting data that includes the use of the CE Mark IVD Histolog Scanner for the breast lumpectomy margin assessment.
Study NCT04761705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JV-GL1
Description: Experimental Treatment
Study NCT04761705 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost 0.005% Ophthalmic Solution
Description: Active Control
Study NCT06296654 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empowerment-Based Interventions
Description: The Empowerment-Based Interventions was used for the study group. It is an integrative educational program under the patient-centered care approach emphasizing collaborative patient interaction. The EBI was implemented through structured (a) small-group d
Study NCT06296654 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Health Education
Description: Patients in the control group received standard health education from SCD clinics in the HC. The clinic employs a multidisciplinary team, including a nurse, a physician, a health record clerk, a laboratory technician, a social worker, and a health promotion specialist, to provide integrated patient health services. It consists of both preventative and curative services. The nurses at the health center provide patients with information regarding factors that may cause vaso-occlusion and precipitate VOCs when to seek emergency care and educate patients on the significance of regular medical examinations and screening using different standardized audiovisual aids.
Study NCT06088849 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Venipuncture
Description: The lactating mother will be asked to collect milk samples and donate 2 blood samples, which is not a part of their normal follow-up/treatment. We will also aks the parents if we can collect a blood sample fo the infant (0-6 months).
Study NCT04735458 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Procedure/Surgery: Response Inhibition and Deep Brain Stimulation in Parkinson's disease
Description: After creation of the burr hole and prior to DBS electrode placement, 1-2 subdural strip electrodes will be placed anteriorly or posteriorly from the cranial opening. These electrodes are routinely placed using this technique for seizure mapping, with arrays of electrodes (up to 6) being placed around the perimeter of the opening.14 Subdural strips vary in length and contact size (e.g., the 6-contact Ad-Tech strip), and are currently placed predominantly for studies of sensorimotor function,13 including at our institution (IRB-140327003). Placement over prefrontal areas is performed at other institutions.11-13 The DBS surgery will then proceed according to routine practice, and following lead placement in the optimal desired location, the research task paradigm will begin.